3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Conditions
Carcinoma, Renal Cell
7
Kidney Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Neoplasm Metastasis
2
Clear-cell metastatic renal cell carcinoma
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Ovarian Neoplasms
1
Mesothelioma, Malignant
1
Mesothelioma
1
Lung Neoplasms
1
Fallopian Tube Neoplasms
1
Cystadenocarcinoma, Serous
1
Colorectal Neoplasms
1
Carcinosarcoma
1
Carcinoma
1
Breast Neoplasms
1
Advanced Renal Cell Carcinoma (RCC)
1
Adenocarcinoma, Mucinous
1
Interventions
Pemetrexed
7
Cisplatin
7
Cyclophosphamide
5
pembrolizumab
4
fludarabine
4
Platinum
3
Drug Therapy
3
aldesleukin
2
Nivolumab
2
Ipilimumab
2
Interleukin-2
2
1,2-diaminocyclohexaneplatinum II citrate
2
vatalanib
1
spartalizumab
1
regorafenib
1
napabucasin
1
methoxyamine
1
fludarabine phosphate
1
enzalutamide
1
cediranib
1
avelumab
1
atezolizumab
1
anetumab ravtansine
1
Vorinostat
1
Thiostrepton
1
Tetrahydrouridine
1
Radiosurgery
1
Megestrol Acetate
1
Levoleucovorin
1
Leucovorin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Mesothelioma, Malignant
×
Axitinib
×
Clear all
NCT01211275
2017-02-28
N08CPA
The Netherlands Cancer Institute
Phase 1/2
Completed
32 enrolled